Minimal Residual Disease (MRD) as a Surrogate Endpoint in Chronic Lymphocytic Leukemia (CLL) Workshop Meeting Roster February 27, 2013 FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center

First Page		Document Content
Clinical pharmacology Food and Drug Administration Pharmacology Therapeutics United States Public Health Service Center for Drug Evaluation and Research B-cell chronic lymphocytic leukemia Hematology Brian Monahan Medicine Health Pharmaceutical sciences		Minimal Residual Disease (MRD) as a Surrogate Endpoint in Chronic Lymphocytic Leukemia (CLL) Workshop Meeting Roster February 27, 2013 FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 18,60 KB Share Document on Facebook

	Lifebank_Logo_withTag-centered DocID: 1rakV - View Document
	Genome Informatics 15(2): 201–Kernel Mixture Survival Models for Identifying Cancer Subtypes, Predicting Patient’s Cancer Types DocID: 1qki5 - View Document
	Interim statement from the BCSH CLL Guidelines Panel George A Follows1, Adrian Bloor2, Claire Dearden3, Steve Devereux4, Christopher P Fox5, Peter Hillmen6, Ben Kennedy7, Helen McCarthy8, Nilima Parry-Jones9, Piers EM Pa DocID: 1qeKO - View Document
	PC-691-T100 Monoclonal Antibody to CD5 PerCP (100 tests) Clone: DocID: 1p8uO - View Document
	1P-482-T025 Monoclonal Antibody to CD5 Phycoerythrin (PE) conjugated (25 tests) Clone: DocID: 1oZDQ - View Document